Methotrexate induces production of IL-1 and IL-6 in the monocytic cell line U937

Arthritis Research and Therapy

Volumn 16, Issue 1, 2014, Pages

  Olsen, Nancy J ^a   Spurlock III, Charles F ^b   Aune, Thomas M ^b  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; IL6 PROTEIN, HUMAN; INTERLEUKIN 1; INTERLEUKIN 6; METHOTREXATE;

APOPTOSIS; BIOSYNTHESIS; CELL SURVIVAL; DRUG EFFECTS; FLOW CYTOMETRY; HUMAN; JURKAT CELL LINE; METABOLISM; MONOCYTE; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; U937 CELL LINE;

ANTI-INFLAMMATORY AGENTS; APOPTOSIS; CELL SURVIVAL; FLOW CYTOMETRY; HUMANS; INTERLEUKIN-1; INTERLEUKIN-6; JURKAT CELLS; METHOTREXATE; MONOCYTES; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; U937 CELLS;

EID: 84892457938     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4444     Document Type: Article

References (28)

1. Hanno R, Gruber GG, Owen LG, Callen JP. Methotrexate in psoriasis. A brief review of indications, usage, and complications of methotrexate therapy. J Am Acad Dermatol 1980, 2:171-174.
2. Alarcón GS. Methotrexate use in rheumatoid arthritis. A clinician's perspective. Immunopharmacology 2000, 47:259-271. 10.1016/S0162-3109(00)00184-3, 10878293.
3. Jolivet J, Cowan KH, Curt GA, Clendeninn NJ, Chabner BA. The pharmacology and clinical use of methotrexate. N Engl J Med 1983, 309:1094-1104. 10.1056/NEJM198311033091805, 6353235.
4. Pincus T, Yazici Y, Sokka T, Aletaha D, Smolen JS. Methotrexate as the " anchor drug" for the treatment of early rheumatoid arthritis. Clin Exp Rheumatol 2003, 21:S179-S185.
5. van der Heijde D, Burmester G, Melo-Gomes J, Codreanu C, Mola EM, Pedersen R, Freundlich B, Chang DJ, Investigators ES. The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapy. Ann Rheum Dis 2008, 67:182-188. 10.1136/ard.2007.076166, 17728331.
6. Pirker-Frühauf UM, Friesenbichler J, Urban EC, Obermayer-Pietsch B, Leithner A. Osteoporosis in children and young adults: a late effect after chemotherapy for bone sarcoma. Clin Orthop Relat Res 2012, 470:2874-2885. 10.1007/s11999-012-2448-7, 3441998, 22806259.
7. Olsen NJ, Murray LM. Antiproliferative effects of methotrexate on peripheral blood mononuclear cells. Arthritis Rheum 1989, 32:378-385. 10.1002/anr.1780320404, 2784965.
8. Chan ES, Cronstein BN. Methotrexate-how does it really work?. Nat Rev Rheumatol 2010, 6:175-178. 10.1038/nrrheum.2010.5, 20197777.
9. Herman S, Zurgil N, Deutsch M. Low dose methotrexate induces apoptosis with reactive oxygen species involvement in T lymphocytic cell lines to a greater extent than in monocytic lines. Inflamm Res 2005, 54:273-280. 10.1007/s00011-005-1355-8, 16134056.
10. Spurlock CF, Aune ZT, Tossberg JT, Collins PL, Aune JP, Huston JW, Crooke PS, Olsen NJ, Aune TM. Increased sensitivity to apoptosis induced by methotrexate is mediated by JNK. Arthritis Rheum 2011, 63:2606-2616. 10.1002/art.30457, 3165146, 21618198.
11. Blits M, Jansen G, Assaraf YG, van de Wiel MA, Lems WF, Nurmohamed MT, van Schaardenburg D, Voskuyl AE, Wolbink GJ, Vosslamber S, Verweij CL. Methotrexate normalizes upregulated folate pathway genes in rheumatoid arthritis. Arthritis Rheum 2013, 65:2791-2802. 10.1002/art.38094, 23897011.
12. Morales-Rojas T, Viera N, Morón-Medina A, Alvarez CJ, Alvarez A. Proinflammatory cytokines during the initial phase of oral mucositis in patients with acute lymphoblastic leukaemia. Int J Paediatr Dent 2012, 22:191-196. 10.1111/j.1365-263X.2011.01175.x, 21919984.
13. de Koning BA, van Dieren JM, Lindenbergh-Kortleve DJ, van der Sluis M, Matsumoto T, Yamaguchi K, Einerhand AW, Samsom JN, Pieters R, Nieuwenhuis EE. Contributions of mucosal immune cells to methotrexate-induced mucositis. Int Immunol 2006, 18:941-949. 10.1093/intimm/dxl030, 16636014.
14. Hamada K, Kakigawa N, Sekine S, Shitara Y, Horie T. Disruption of ZO-1/claudin-4 interaction in relation to inflammatory responses in methotrexate-induced intestinal mucositis. Cancer Chemother Pharmacol 2013, 72:757-765. 10.1007/s00280-013-2238-2, 23963446.
15. King TJ, Georgiou KR, Cool JC, Scherer MA, Ang ES, Foster BK, Xu J, Xian CJ. Methotrexate chemotherapy promotes osteoclast formation in the long bone of rats via increased pro-inflammatory cytokines and enhanced NF-κB activation. Am J Pathol 2012, 181:121-129. 10.1016/j.ajpath.2012.03.037, 22642908.
16. Spurlock CF, Tossberg JT, Fuchs HA, Olsen NJ, Aune TM. Methotrexate increases expression of cell cycle checkpoint genes via JNK activation. Arthritis Rheum 2012, 64:1780-1789. 10.1002/art.34342, 3310965, 22183962.
17. Olsen NJ, Schleich MA, Karp DR. Multifaceted effects of hydroxychloroquine in human disease. Semin Arthritis Rheu 2013, 43:264-272.
18. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983, 65:55-63. 10.1016/0022-1759(83)90303-4, 6606682.
19. Montesinos MC, Yap JS, Desai A, Posadas I, McCrary CT, Cronstein BN. Reversal of the antiinflammatory effects of methotrexate by the nonselective adenosine receptor antagonists theophylline and caffeine: evidence that the antiinflammatory effects of methotrexate are mediated via multiple adenosine receptors in rat adjuvant arthritis. Arthritis Rheum 2000, 43:656-663. 10.1002/1529-0131(200003)43:3<656::AID-ANR23>3.0.CO;2-H, 10728760.
20. Phillips DC, Woollard KJ, Griffiths HR. The anti-inflammatory actions of methotrexate are critically dependent upon the production of reactive oxygen species. Br J Pharmacol 2003, 138:501-511. 10.1038/sj.bjp.0705054, 1573681, 12569075.
21. Kim YJ, Song M, Ryu JC. Mechanisms underlying methotrexate-induced pulmonary toxicity. Expert Opin Drug Saf 2009, 8:451-458. 10.1517/14740330903066734, 19538103.
22. Cranney AB, McKendry RJ, Wells GA, Ooi DS, Kanigsberg ND, Kraag GR, Smith CD. The effect of low dose methotrexate on bone density. J Rheumatol 2001, 28:2395-2399.
23. Braun T, Schett G. Pathways for bone loss in inflammatory disease. Curr Osteoporos Rep 2012, 10:101-108. 10.1007/s11914-012-0104-5, 22527726.
24. Segal R, Mozes E, Yaron M, Tartakovsky B. The effects of methotrexate on the production and activity of interleukin-1. Arthritis Rheum 1989, 32:370-377. 10.1002/anr.1780320403, 2784964.
25. Thomas R, Carroll GJ. Reduction of leukocyte and interleukin-1 beta concentrations in the synovial fluid of rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 1993, 36:1244-1252. 10.1002/art.1780360909, 8216418.
26. Hashizume M, Yoshida H, Tanaka K, Suzuki M, Matsumoto I, Sumida T, Mihara M. Interleukin-6 regulates anti-arthritic effect of methotrexate via reduction of SLC19A1 expression in a mouse arthritis model. Arthritis Res Ther 2012, 14:R96. 10.1186/ar3821, 3446470, 22546471.
27. Yoshida M, Kanno Y, Ishisaki A, Tokuda H, Hirade K, Nakajima K, Katagiri Y, Shimizu K, Kozawa O. Methotrexate suppresses inflammatory agonist induced interleukin 6 synthesis in osteoblasts. J Rheumatol 2005, 32:787-795.
28. Fagerli KM, Lie E, van der Heijde D, Heiberg MS, Lexberg AS, Rødevand E, Kalstad S, Mikkelsen K, Kvien TK. The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study. Ann Rheum Dis 2013, 73:132-137.